trial · primary record
ManNAc
Focal Segmental Glomerulosclerosis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2030-12-01 |
| Primary endpoint | Determine the efficacy of ManNAc therapy in reducing proteinuria (UPCR) in subjects with podocyte diseases. |
| Registry ID | NCT06664814 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:10.779Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06664814
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.